VX-522 mRNA therapy
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Vertex Pharmaceuticals Incorporated
Overview
VX-522 mRNA therapy is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
VX-522 mRNA therapy clinical trials
Explore related
Medical disclaimer. This page summarizes research about VX-522 mRNA therapy for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.